Abstract

Buprenorphine/Naloxone (Suboxone®) is an efficacious treatment for opioid use disorder (OUD) due to its more convenient dosing, superior safety profile, and decreased incidence of negative side effects when compared to other forms of medications for opioid use disorder (MOUD). In the United States, updated legislation in 2021 entitled, "The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder", released by the Department of Health and Human Services, creates an exemption for the previously required Drug Addiction Treatment Act of 2000 (DATA) waiver for buprenorphine prescribing for clinicians. This legislation was born out of a need for making MOUD more accessible for patients living with OUD as rates of opioid-related deaths in the United States have continued to rise and have increased disproportionately during the time period of the COVID-19 pandemic. This legislation has the potential to improve access to MOUD across all geographic locations, but may have the most profound impact in rural areas where significant disparities and challenges still exist in patients’ ability to access buprenorphine. The purpose of this literature review is to 1) examine how MOUD prescribing has changed after previous legislation changes, 2) explore the current state of buprenorphine access for treatment of OUD in rural America, 3) detail existing barriers in patients' ability to access MOUD, and 4) discuss future directions and considerations as a result of new legislation. This literature review found several existing barriers to receiving MOUD such as increasing costs, insufficient education, significant stigma, and the need for more innovative methods of delivery. We also found that there is currently a large opportunity for growth in the number of rural clinicians able to prescribe buprenorphine, particularly in primary care, that may now occur as a result of this new legislation. Overall, this legislation has the potential to have a positive impact on combating OUD, especially in rural areas, and may be a critical step towards ending the current opioid epidemic in the United States as these described barriers are addressed.

Highlights

  • BackgroundPharmacology of buprenorphine and naloxoneMedications for opioid use disorder (MOUD), formally referred to as medication assisted treatment (MAT), are medications that can be prescribed to patients who want to stop using opioids [1]

  • If education on MOUD becomes more prevalent in medical education, we predict there will be a significant increase in the number of young and newly graduated physicians who feel confident and well-informed on how to treat patients addicted to opioids in their own areas of practice

  • As the opioid epidemic continues to affect the United States and has a disproportionate effect on rural areas, it is critical for legislation to evolve to meet the needs of clinicians who treat OUD and their patients

Read more

Summary

Introduction

Medications for opioid use disorder (MOUD), formally referred to as medication assisted treatment (MAT), are medications that can be prescribed to patients who want to stop using opioids [1]. “The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder provides eligible physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives, who are state-licensed and registered by the DEA to prescribe controlled substances, an exemption from certain statutory certification requirements related to training, counseling and other ancillary services.” [18]. This new and current legislation allows for expanded prescribing access to buprenorphine for the treatment of OUD for up to 30 patients per provider. The purpose of this literature review is to discuss the current state of buprenorphine access and utilization for treatment of OUD in rural America and future directions and considerations as a result of new legislation

Methods
Conclusions
Disclosures
UpToDate
National Alliance on Mental Illness
American Society of Addiction Medicine
14. Rural Health Information Hub
18. Federal Register
26. Jones EB
32. Sigmon SC
Findings
43. American Psychiatric Association
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call